11/09/2016
SeraCare Life Sciences collaborates with ArcherDX on RNA Fusion Reference Standards
Firms will collaborate to support Archer® FusionPlex® NGS-assay customers
Press Releases
10/19/2016
SeraCare Life Sciences Develops Industry’s First Multiplexed Cardiomyopathy Reference Material
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, is announcing the launch of the industry’s first multiplexed reference material for inherited disease testing by next-generation sequencing (NGS) at the 2016 ASHG Annual Meeting in Vancouver.
10/12/2016
SeraCare Life Sciences Announces Preimplantation Genetic Screening (PGS) Reference Materials Partnership
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, today announced it is partnering with AAB Proficiency Testing Service (AAB) for the development and use of preimplantation genetic screening (PGS) reference materials.
09/22/2016
France-Based Laboratoire CERBA Adopts Seraseq™ Aneuploidy Reference Materials for Non-Invasive Prenatal Testing (NIPT)
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, has signed an agreement with Laboratoire CERBA, a leading European reference laboratory specializing in clinical pathology, to provide custom Seraseq™ Aneuploidy Reference Materials for use with Laboratoire CERBA's non-invasive prenatal testing (NIPT) assay.
08/03/2016
SeraCare Life Sciences Debuts its New Website at AACC
SeraCare Life Sciences, a leading partner to clinical laboratories and global in vitro diagnostics manufacturers, announced at the American Association of Clinical Chemistry (AACC) conference today the launch of its newly redesigned website, www.seracare.com.
07/26/2016
SeraCare Launches New QC Software for Clinical Laboratories Running Next-Generation Sequencing Assays
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today that the company's precision medicine business unit has launched a groundbreaking new laboratory QC software specifically for clinical laboratories running next-generation sequencing (NGS)-based assays.
06/16/2016
SeraCare and NIST Partner on Development of Circulating Tumor DNA Reference Standards for Diagnostics
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, and the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) have signed of a three-year Cooperative Research And Development Agreement (CRADA) to advance development of circulating tumor DNA (ctDNA) diagnostic assay reference standard materials.
05/09/2016
SeraCare Launches Industry’s First Recombinant Virus Technology-based AccuPlex™ Zika Reference Material
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, today announces the launch of AccuPlex Zika Reference Material to fast track the development and validation of PCR-based Zika virus assays.
04/20/2016
SeraCare Life Sciences and TOMA Biosciences Enter Into Co-development Partnership
TOMA Biosciences to use Seraseq™ biosynthetic reference material technology in development and validation of their TOMA OS-Seq™ reagent kits
04/18/2016
SeraCare Launches Expanded Offering of Biosynthetic Somatic Tumor Reference Materials for NGS-based Tumor Profiling Assays
SeraCare Launches Expanded Offering of Biosynthetic Somatic Tumor Reference Materials for NGS-based Tumor Profiling Assays
03/07/2016
SeraCare Launches Circulating Tumor DNA Reference Materials for NGS and Digital PCR-based Oncology Assays
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, today announces the launch of two new circulating tumor DNA (ctDNA) products at the 2016 Molecular Medicine Tri-Conference in San Francisco.
01/28/2016
Swift Biosciences and SeraCare Partner on Circulating Tumor DNA Standards for NGS-Based Oncology Assays
Swift Biosciences, developer of innovative technologies for genomics research, and SeraCare Life Sciences, a manufacturer and leading partner to global in-vitro diagnostics manufacturers, has announced a partnership to accelerate development of a novel circulating tumor DNA reference material.
11/03/2015
SeraCare Life Sciences Announces Early Access Programs for ctDNA and RNAFusion Reference Materials
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers and clinical diagnostics laboratories announces two important development milestones to their growing portfolio of next‐generation sequencing (NGS)‐based tools for Precision Medicine.
10/13/2015
SeraCare Launches New Quantitative Reference Materials for NGS‐Based Tumor Profiling Assays
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, announced today that the company’s precision medicine business unit has launched its second product in a growing line of reference materials for next‐generation sequencing (NGS)‐based tumor profiling assays.
07/29/2015
SeraCare Life Sciences Unveils Rebranding Initiative to Support Company’s Expanding Capabilities for Precision Diagnostics
SeraCare Life Sciences, a leading partner to clinical laboratories and global in vitro diagnostics manufacturers, announced at the American Association of Clinical Chemistry (AACC) conference today, that it has launched its rebranding initiative as part of the company’s expanding capabilities for the support of advanced diagnostics development.
07/28/2015
SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, announced today at the American Association of Clinical Chemistry (AACC) meeting that it has signed a licensing agreement with the University of California, San Francisco (UCSF) for the use of Trisomy 21 (T21), Trisomy 18 (T18) and Trisomy 13 (T13) trophoblast cell line material as a component for creating “patient-like” reference materials for Non-Invasive Prenatal Testing (NIPT) of chromosomal abnormalities.
07/27/2015
SeraCare Life Sciences Announces Strategic Partnership with ViveBio to EnableNext Generation Preanalytic Products for the IVD Industry
Combined Technologies Offer IVD Developers New Tools for Collection, Stabilization and QC
07/08/2015
SeraCare Life Sciences’ Precision Medicine Unit Launches New Product to Ensure Accuracy of NGS Assays
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that the company’s new precision medicine business unit has launched its first product, the Seraseq™ Solid Tumor Mutation Mix—I (AF20); a biosynthetic reference material designed to evaluate the performance of next generation sequencing (NGS)-based tumor profiling assays.
06/26/2015
SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, to create reference materials and positive controls for cancer assays.
06/18/2015
SeraCare Makes Key Investment in Expanding R&D Facility; Strengthens Leadership with New Hires
SeraCare Life Sciences, a leading partner to global In Vitro Diagnostics manufacturers, announced today an expansion and upgrade to their Gaithersburg, MD, R&D facility.